Computational pathology is approaching a clinical inflection point, and the bottleneck is no longer algorithmic accuracy but practical deployability. A framework that can match or exceed current AI performance while running on standard hardware — and doing so transparently — would meaningfully lower the barrier to AI-assisted cancer diagnostics in real-world oncology settings.
The EAGLE (Efficient Approach for Guided Local Examination) framework, published in Nature Communications, addresses this gap by mimicking how pathologists actually work: focusing attention on diagnostically informative tissue regions rather than exhaustively processing every tile across a whole-slide image. Benchmarked across 43 classification tasks spanning nine cancer types — including morphological subtyping, biomarker prediction, treatment response, and prognosis — EAGLE outperformed leading patch aggregation methods by up to 23% in classification performance. Critically, it processes a single whole-slide image in approximately 2.27 seconds, representing more than a 99% reduction in computational time versus current foundation models. The architecture combines task-agnostic tile selection with granular feature extraction and produces a unified slide embedding that can integrate into multi-omics pipelines.
The implications extend well beyond speed. Current weakly supervised multiple-instance learning models — the dominant paradigm in computational pathology — function largely as black boxes, making audibility a persistent clinical concern. EAGLE's selective tile approach inherently surfaces the specific image regions driving each prediction, enabling pathologist review and regulatory traceability. This matters because FDA clearance pathways for AI diagnostics increasingly demand interpretability. From a research landscape perspective, the 99% compute reduction is not merely an efficiency gain; it democratizes access, allowing institutions without GPU clusters to run advanced slide-level AI. The 43-task benchmark is among the broadest published for a single framework, lending genuine comparative weight. Primary limitations include the absence of prospective clinical validation and the need to assess performance on rare cancer subtypes and non-Western tissue preparation protocols.